WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 5 fonti

Wegovy Pill weight-loss drug approved for use in Britain

As exclusively revealed by the Daily Mail last week, the Wegovy Pill - the tablet form of the once-weekly Wegovy injection - has been greenlit by health officials.

Raccontata dadailymail.commirror.co.uktheguardian.compolitiken.dkbenzinga.com

Confronto fonti

5 prospettive sulla stessa storia
AI · summaries
dailymail.comStai leggendo11 h fa

Wegovy Pill weight-loss drug approved for use in Britain

As exclusively revealed by the Daily Mail last week, the Wegovy Pill - the tablet form of the once-weekly Wegovy injection - has been greenlit by health officials.

originale

Timeline cronologica

  1. lunedì 8 giugno 2026·dailymail.com

    New daily pill helps obese patients lose a tenth of bodyweight

    An experimental daily weight loss pill helped people shift more than ten per cent of their bodyweight after six months, research has found.

  2. giovedì 11 giugno 2026·dailymail.com

    Wegovy Pill weight-loss drug approved for use in Britain

    As exclusively revealed by the Daily Mail last week, the Wegovy Pill - the tablet form of the once-weekly Wegovy injection - has been greenlit by health officials.

theguardian.com
11 h fa

Wegovy weight-loss pills to be available for patients in UK to buy

Regulator approval means patients who meet criteria such as having obesity will be able to purchase pills with private prescription

Leggi questa versione → originale
mirror.co.uk11 h fa

Breakthrough as UK's first weight loss tablet is given green light

Novo Nordisk riceve approvazione UK per Wegovy orale: 25mg giornalieri, primo GLP-1 in pillola; trial mostra 17% perdita di peso media vs 3% placebo dopo 64 settimane. Amplia l'accesso ai trattamenti obesity, segnalando opportunità per digital health e telemedicine nel monitoraggio.

Leggi questa versione → originale
benzinga.com9 h fa

Novo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet - Novo Nordisk (NYSE:NVO)

Novo Nordisk wins U.K. approval for Wegovy pill, offering adults a daily oral weight-loss option backed by Phase 3 trial data.

Leggi questa versione → originale
politiken.dk11 h fa

Første europæiske land godkender Wegovy-pillen

Politiken følger den økonomiske udvikling - bliv klogere på toldkrig, jobmarkedet, aktiekurser, boligpriser og påvirkningerne af din privatøkonomi.

Leggi questa versione → originale
  • giovedì 11 giugno 2026·mirror.co.uk

    Breakthrough as UK's first weight loss tablet is given green light

    A new prescription-only weight loss tablet has been approved for use in the UK for people who are overweight and have a related condition like high blood pressure

  • giovedì 11 giugno 2026·theguardian.com

    Wegovy weight-loss pills to be available for patients in UK to buy

    Regulator approval means patients who meet criteria such as having obesity will be able to purchase pills with private prescription

  • giovedì 11 giugno 2026·politiken.dk

    Første europæiske land godkender Wegovy-pillen

    Politiken følger den økonomiske udvikling - bliv klogere på toldkrig, jobmarkedet, aktiekurser, boligpriser og påvirkningerne af din privatøkonomi.

  • giovedì 11 giugno 2026·benzinga.com

    Novo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet - Novo Nordisk (NYSE:NVO)

    Novo Nordisk wins U.K. approval for Wegovy pill, offering adults a daily oral weight-loss option backed by Phase 3 trial data.